var data={"title":"Etanercept (including biosimilars of etanercept): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Etanercept (including biosimilars of etanercept): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6147?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=etanercept-including-biosimilars-of-etanercept-patient-drug-information\" class=\"drug drug_patient\">see &quot;Etanercept (including biosimilars of etanercept): Patient drug information&quot;</a> and <a href=\"topic.htm?path=etanercept-including-biosimilars-of-etanercept-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Etanercept (including biosimilars of etanercept): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6655343\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Serious infections:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Patients treated with etanercept are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients treated with etanercept who developed these infections were taking concomitant immunosuppressants, such as methotrexate or corticosteroids.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Discontinue etanercept if a patient develops a serious infection or sepsis.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Reported infections include the following:</p>\n        <p style=\"text-indent:-2em;margin-left:6em;\">Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Test patients for latent TB before etanercept use and during therapy. Initiate treatment for latent infection prior to etanercept use.</p>\n        <p style=\"text-indent:-2em;margin-left:6em;\">Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Consider empiric antifungal therapy in patients at risk for invasive fungal infections who develop severe systemic illness.</p>\n        <p style=\"text-indent:-2em;margin-left:6em;\">Bacterial, viral, and other infections caused by opportunistic pathogens, including Legionella and Listeria.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Carefully consider the risks and benefits of treatment with etanercept prior to initiating therapy in patients with long-term or recurrent infections.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Closely monitor patients for the development of signs and symptoms of infection during and after treatment with etanercept, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Malignancies:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with tumor necrosis factor (TNF) blockers, including etanercept.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F167887\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Enbrel;</li>\n      <li>Enbrel Mini;</li>\n      <li>Enbrel SureClick</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F167888\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Brenzys;</li>\n      <li>Enbrel;</li>\n      <li>Erelzi</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F167912\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antirheumatic, Disease Modifying;</li>\n      <li>\n        Tumor Necrosis Factor (TNF) Blocking Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F167891\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: </b> Erelzi is approved as biosimilar to Enbrel.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:left;\">\n      <b>Ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis:</b> SubQ: <b>Note:</b> May continue methotrexate, glucocorticoids, salicylates, NSAIDs, or analgesics during etanercept therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:left;\">Once-weekly dosing: 50 mg once weekly; maximum dose (rheumatoid arthritis): 50 mg/week.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:left;\">Twice-weekly dosing (off-label dose): 25 mg twice weekly (Bathon 2000; Calin 2004; Davis 2003; Genovese 2002; Mease 2000; Mease 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Plaque psoriasis: </b> SubQ:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Initial: 50 mg twice weekly for 3 months (starting doses of 25 or 50 mg once weekly have also been used successfully)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Maintenance dose: 50 mg once weekly</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute graft-versus-host disease (GVHD), treatment (off-label use):</b> SubQ: 0.4 mg/kg (maximum: 25 mg/dose) twice weekly for 8 weeks (in combination with methylprednisolone) (Levine 2008)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F167901\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=etanercept-including-biosimilars-of-etanercept-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Etanercept (including biosimilars of etanercept): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Erelzi is approved as biosimilar to Enbrel.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:left;\">\n      <b>Juvenile idiopathic arthritis:</b> Children &ge;2 years and Adolescents: SubQ: <b>Note:</b> May continue glucocorticoids, NSAIDs, or analgesics during etanercept therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:left;\">Once-weekly dosing:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:left;\">&lt;63 kg: 0.8 mg/kg (maximum: 50 mg/dose) once weekly. <b>Note:</b> There is no dosage form for Erelzi that allows weight-based dosing for pediatric patients &lt;63 kg.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:left;\">&ge;63 kg: 50 mg once weekly.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:left;\">Twice-weekly dosing (off-label dose): 0.4 mg/kg (maximum: 25 mg/dose) twice weekly (Lovell 2006).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:left;\">\n      <b>Plaque psoriasis (Enbrel only):</b> Children &ge;4 years and Adolescents: SubQ:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:left;\">&lt;63 kg: 0.8 mg/kg (maximum: 50 mg/dose) once weekly.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:left;\">&ge;63 kg: 50 mg once weekly</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:left;\">\n      <b>Acute graft-versus-host disease (GVHD), treatment (off-label use):</b> Children &ge;1 year and Adolescents: SubQ: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F167892\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14471443\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14471444\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F167868\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Auto-injector, Subcutaneous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Enbrel SureClick: 50 mg/mL (0.98 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Cartridge, Subcutaneous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Enbrel Mini: 50 mg/mL (0.98 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Prefilled Syringe, Subcutaneous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Enbrel: 25 mg/0.5 mL (0.51 mL); 50 mg/mL (0.98 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Subcutaneous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Enbrel: 25 mg (1 ea) [contains benzyl alcohol]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F167854\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51112571\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Solution Auto-injector, Subcutaneous [preservative free]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Erelzi: 50 mg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Solution Prefilled Syringe, Subcutaneous [preservative free]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Erelzi: 25 mg/0.5 mL; 50 mg/mL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F48847984\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Erelzi (etanercept-szzs): FDA approved August 2016; anticipated availability is currently unknown. Erelzi is approved as biosimilar to Enbrel, but not as an interchangeable product.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7874648\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/103795s5561lbl.pdf#page=34&amp;token=TlvsGN6yU3iu7E1WHJZFY10u0eNNUj+cPVADoN+JE+4xeDvyf7dE4wvUB7Ltg9+2bE+lyslP5WRGuhw8LwGy5+Abc0bgQfnSZil8NFS3pLmXrl+ij1K3/MMCNEGEkKf1&amp;TOPIC_ID=8925\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/103795s5561lbl.pdf#page=34</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F167870\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">SubQ: Administer subcutaneously. Rotate injection sites; may inject into the thigh (preferred), abdomen (avoiding the 2-inch area around the navel), or outer areas of upper arm. New injections should be given at least 1 inch from an old site and never into areas where the skin is tender, bruised, red, or hard; any raised thick, red, or scaly skin patches or lesions; or areas with scars or stretch marks. For a more comfortable injection, allow autoinjectors, prefilled syringes, and dose trays to reach room temperature for 15 to 30 minutes (&ge;30 minutes for autoinjector) prior to injection; do not remove the needle cover while allowing product to reach room temperature. There may be small white particles of protein in the solution; this is not unusual for proteinaceous solutions. <b>Note:</b> If the health care provider determines that it is appropriate, patients may self-inject after proper training in injection technique.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F167869\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ankylosing spondylitis:</b> Reducing signs and symptoms in patients with active ankylosing spondylitis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Plaque psoriasis (Enbrel):</b> Treatment of patients &ge;4 years of age with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Polyarticular juvenile idiopathic arthritis:</b> Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients &ge;2 years of age.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Psoriatic arthritis (Enbrel):</b> Reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in patients with psoriatic arthritis. Etanercept can be used with or without methotrexate.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Rheumatoid arthritis:</b> Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis (RA). Etanercept can be initiated in combination with methotrexate or used alone.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25473874\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Hidradenitis suppurativa; Pyoderma gangrenosum; Graft-versus-host disease (treatment)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7914269\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Enbrel may be confused with Levbid</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F167861\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (3% to 13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (3% to 16%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Infection (50% to 81%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Injection site reaction (adults: 15% to 43%; children: 7%; bleeding, bruising, erythema, itching, pain, or swelling; mild to moderate and usually decreases with subsequent injections)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Upper respiratory tract infection (38% to 65%), respiratory tract infection (21% to 54%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Antibody development (non-neutralizing; 4% to 16%), positive ANA titer (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Pruritus (2% to 5%), urticaria ( 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Hypersensitivity reaction (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (2% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Cellulitis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Gastroenteritis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Abscess, influenza, sepsis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Osteomyelitis, septic arthritis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Pyelonephritis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Bronchitis, pneumonia, sinusitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Anemia, angioedema, aplastic anemia, aseptic meningitis, aspergillosis, autoimmune hepatitis, cardiac failure, chest pain, cutaneous lupus erythematous, demyelinating disease of the central nervous system, erythema multiforme, fungal infection (including histoplasmosis), Guillain-Barr&eacute; syndrome, hepatotoxicity (idiosyncratic) (Chalasani 2014), herpes zoster, increased serum transaminases, inflammatory bowel disease, interstitial pulmonary disease, leukemia, leukopenia, lupus-like syndrome, lymphadenopathy, malignant lymphoma, malignant melanoma, malignant neoplasm, Merkel cell carcinoma, multiple sclerosis, neutropenia, optic neuritis, pancytopenia, paresthesia, pneumonia due to <i>Pneumocystis carinii</i>, psoriasis (including new onset, palmoplantar, pustular, or exacerbation), reactivation of HBV, sarcoidosis, scleritis, seizure, skin carcinoma, Stevens-Johnson syndrome, subcutaneous nodule, thrombocytopenia, toxic epidermal necrolysis, transverse myelitis, tuberculosis (including pulmonary and extrapulmonary), uveitis, varicella zoster infection, vasculitis (cutaneous and systemic)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F167873\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Sepsis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to etanercept or any component of the formulation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F167858\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylaxis/hypersensitivity reactions: Allergic reactions may occur, if an anaphylactic reaction or other serious allergic reaction occurs, administration should be discontinued immediately and appropriate therapy initiated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Autoimmune disorder: Positive antinuclear antibody titers have been detected in patients (with negative baselines). Rare cases of autoimmune disorder, including lupus-like syndrome or autoimmune hepatitis, have been reported; monitor and discontinue if symptoms develop.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Demyelinating CNS disease: Rare cases of new-onset or exacerbation of CNS demyelinating disorders have occurred; may present with mental status changes and some may be associated with permanent disability. Optic neuritis, transverse myelitis, multiple sclerosis, Guillain-Barr&eacute; syndrome, and other peripheral demyelinating neuropathies have been reported. Use with caution in patients with preexisting or recent-onset CNS demyelinating disorders.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Heart failure: Worsening and new-onset heart failure has been reported, including in patients without known preexisting cardiovascular disease. Use with caution in patients with heart failure or decreased left ventricular function. In a scientific statement from the American Heart Association, TNF blockers have been determined to be agents that may either cause direct myocardial toxicity or exacerbate underlying myocardial dysfunction (magnitude: major) (AHA [Page 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematologic disorders: Rare cases of pancytopenia and aplastic anemia have been reported (some fatal). Patients must be advised to seek medical attention if they develop signs and symptoms suggestive of blood dyscrasias; discontinue if significant hematologic abnormalities are confirmed. Use with caution in patients with a history of significant hematologic abnormalities.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatitis B: Rare reactivation of hepatitis B (HBV) has occurred in chronic carriers of the virus, usually in patients receiving concomitant immunosuppressants (has been fatal); evaluate for HBV prior to initiation in all patients. Monitor during and for several months following discontinuation of treatment in HBV carriers; consider interruption of therapy if reactivation occurs and treat appropriately with antiviral therapy. If resumption of therapy is deemed necessary, exercise caution and monitor patient closely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infections: <b>[US Boxed Warning]: Patients receiving etanercept are at increased risk for serious infections which may result in hospitalization and/or fatality; infections usually developed in patients receiving concomitant immunosuppressive agents (eg, methotrexate, corticosteroids) and may present as disseminated (rather than local) disease. Active tuberculosis (including reactivation of latent tuberculosis), invasive fungal (including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, and pneumocystosis) and bacterial, viral, or other opportunistic infections (including Legionellosis and Listeriosis) have been reported. Monitor closely for signs/symptoms of infection during and after treatment. Discontinue for serious infection or sepsis. Consider risks versus benefits prior to initiating therapy in patients with chronic or recurrent infection. Consider empiric antifungal therapy in patients who are at risk for invasive fungal infections who develop severe systemic illness.</b> Caution should be exercised when considering use in elderly patients, patients with chronic or recurrent infections, patients exposed to tuberculosis, patients with a history of an opportunistic infection, in patients with conditions that predispose them to infections (eg, advanced or poorly controlled diabetes), residence/travel from areas of endemic mycoses (blastomycosis, coccidioidomycosis, histoplasmosis), or with latent infections. Do not initiate etanercept therapy in patients with an active infection, including clinically important localized infection. Patients who develop a new infection while undergoing treatment should be monitored closely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Malignancy: <b>[US Boxed Warning]: Lymphoma and other malignancies (some fatal) have been reported in children and adolescents receiving TNF-blocking agents, including etanercept.</b> Half of the malignancies reported in children and adolescents were lymphomas (Hodgkin and non-Hodgkin) while other cases varied and included rare malignancies usually associated with immunosuppression and malignancies not typically observed in this population. The impact of etanercept on the development and course of malignancy is not fully defined. Compared to the general population, an increased risk of lymphoma has been noted in clinical trials; however, rheumatoid arthritis alone has been previously associated with an increased rate of lymphoma and leukemia. Lymphomas and other malignancies were also observed (at rates higher than expected for the general population) in adult patients receiving etanercept. Hepatosplenic T-cell lymphoma (HSTCL), a rare T-cell lymphoma, has also been associated with TNF-blocking agents, primarily reported in adolescent and young adult males with Crohn disease or ulcerative colitis. Melanoma, nonmelanoma skin cancer, and Merkel cell carcinoma have been reported. Perform periodic skin examinations in all patients during therapy, particularly those at increased risk of skin cancer.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tuberculosis: <b>[US Boxed Warning]: Active tuberculosis (disseminated or extrapulmonary), including reactivation of latent tuberculosis, has been reported in patients receiving etanercept.</b><b> Evaluate patients for tuberculosis risk factors and latent tuberculosis infection (with a tuberculin skin test) prior to and during therapy. Treatment for latent tuberculosis should be initiated before use. </b><b>Patients with initial negative tuberculin skin tests should receive continued monitoring for tuberculosis during and after treatment. </b> Consider antituberculosis treatment if an adequate course of treatment cannot be confirmed in patients with a history of latent or active tuberculosis or with risk factors despite negative skin test. Some patients who tested negative prior to therapy have developed active infection; tests for latent tuberculosis infection may be falsely negative while on etanercept therapy. Use with caution in patients who have traveled to or resided in regions where tuberculosis is endemic. Monitor for signs and symptoms of tuberculosis in all patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Alcoholic hepatitis: Use with caution in patients with moderate to severe alcoholic hepatitis. Compared to placebo, the mortality rate in patients treated with etanercept was similar at one month but significantly higher after 6 months.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure disorders: Use with caution in patients with a history of seizures; new-onset or exacerbation of seizures have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Wegener granulomatosis: Use is not recommended in patients with Wegener granulomatosis who are receiving immunosuppressive therapy due to higher incidence of noncutaneous solid malignancies.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Infection has been reported at a higher incidence; use caution in elderly patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Malignancies have been reported among children and adolescents.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Varicella virus exposure: Patients with a significant exposure to varicella virus should temporarily discontinue therapy; treatment with varicella zoster immune globulin should be considered.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Diluent for injection may contain benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Latex: Some dosage forms may contain dry natural rubber (latex).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunizations: Patients should be brought up to date with all immunizations before initiating therapy. Live vaccines should not be given concurrently; there is no data available concerning secondary transmission of live vaccines in patients receiving therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299288\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F167863\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8925&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Abatacept: Anti-TNF Agents may enhance the adverse/toxic effect of Abatacept. An increased risk of serious infection during concomitant use has been reported. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anakinra: Anti-TNF Agents may enhance the adverse/toxic effect of Anakinra. An increased risk of serious infection during concomitant use has been reported. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Belimumab: Etanercept may enhance the adverse/toxic effect of Belimumab. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Canakinumab: Anti-TNF Agents may enhance the adverse/toxic effect of Canakinumab. Specifically, the risk for serious infections and/or neutropenia may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Certolizumab Pegol: Anti-TNF Agents may enhance the immunosuppressive effect of Certolizumab Pegol. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cyclophosphamide: Etanercept may enhance the adverse/toxic effect of Cyclophosphamide. An increased risk of solid cancer development may be present. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">InFLIXimab: Etanercept may enhance the immunosuppressive effect of InFLIXimab. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rilonacept: Anti-TNF Agents may enhance the adverse/toxic effect of Rilonacept. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiopurine Analogs: Anti-TNF Agents may enhance the adverse/toxic effect of Thiopurine Analogs. Specifically, the risk for T-cell non-Hodgkin's lymphoma (including hepatosplenic T-cell lymphoma) may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May enhance the immunosuppressive effect of Anti-TNF Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Anti-TNF Agents may enhance the adverse/toxic effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vedolizumab: Anti-TNF Agents may enhance the adverse/toxic effect of Vedolizumab. <i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F167876\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. Etanercept crosses the placenta. Following in utero exposure, concentrations in the newborn at delivery are 3% to 32% of the maternal serum concentration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F167877\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Etanercept is present in breast milk in low concentrations and is minimally absorbed by a breastfeeding infant (limited data). According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6045563\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor improvement of symptoms and physical function assessments.  Latent TB screening prior to initiating and during therapy; signs/symptoms of infection (prior to, during, and following therapy); CBC with differential; signs/symptoms/worsening of heart failure; HBV screening prior to initiating (all patients), HBV carriers (during and for several months following therapy); signs and symptoms of hypersensitivity reaction; symptoms of lupus-like syndrome; signs/symptoms of malignancy (eg, splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F167857\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Etanercept is a recombinant DNA-derived protein composed of tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. Etanercept binds tumor necrosis factor (TNF) and blocks its interaction with cell surface receptors. TNF plays an important role in the inflammatory processes and the resulting joint pathology of rheumatoid arthritis (RA), polyarticular-course juvenile idiopathic arthritis (JIA), ankylosing spondylitis (AS), and plaque psoriasis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F167872\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: ~2 to 3 weeks; RA: 1 to 2 weeks; Maximum effect: RA: Full effect is usually seen within 3 months</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Absorbed slowly after SubQ injection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: SubQ: 60%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: SubQ: Children &ge;4 years and Adolescents (JIA): Mean range: 70 to 94.8 hours (range: 31.2 to 104.8 hours) (Yim 2005); Adults (RA): 102 &plusmn; 30 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: RA: SubQ: 69 &plusmn; 34 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clearance: Children and Adolescents 4 to 17 years: 46 mL/hour/m<sup>2 </sup>(Enbrel prescribing information 1998); Adults: 160 &plusmn; 80 mL/hour</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F167875\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Enbrel Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (1): $730.80</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Auto-injector</b> (Enbrel SureClick Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/mL (0.98 mL): $1,461.60</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Cartridge</b> (Enbrel Mini Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/mL (0.98 mL): $1,461.60</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Enbrel Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg/0.5 mL (0.51 mL): $730.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/mL (0.98 mL): $1,461.60</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F167878\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Benepali (GB, IE);</li>\n      <li>Enbrel (AE, AR, AT, AU, BB, BE, BG, BH, BR, CH, CL, CN, CO, CY, CZ, DE, DK, EC, EE, ES, FI, FR, GB, GR, HK, HR, HU, ID, IE, IL, IN, IS, IT, JO, JP, KR, KW, LB, LT, LU, LV, MT, MX, MY, NL, NO, NZ, PE, PH, PL, PT, QA, RO, RU, SA, SE, SG, SI, SK, TH, TR, TW, UA, VE, VN);</li>\n      <li>Infinatam (CR, DO, GT, HN, NI, PA, SV)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etanercept-including-biosimilars-of-etanercept-drug-information/abstract-text/11487763/pubmed\" target=\"_blank\" id=\"11487763\">11487763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11096165\"></a>Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. <i>N Engl J Med</i>. 2000;343(22):1586-1593.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etanercept-including-biosimilars-of-etanercept-drug-information/abstract-text/11096165/pubmed\" target=\"_blank\" id=\"11096165\">11096165</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Breedveld F, &ldquo;New Tumor Necrosis Factor-Alpha Biologic Therapies for Rheumatoid Arthritis,&rdquo; <i>Eur Cytokine Netw</i>, 1998, 9(3):233-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etanercept-including-biosimilars-of-etanercept-drug-information/abstract-text/9831171/pubmed\" target=\"_blank\" id=\"9831171\">9831171</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brenzys (etanercept) [product monograph]. Kirkland, Quebec, Canada: Merck Canada Inc; August 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15345498\"></a>Calin A, Dijkmans BA, Emery P, et al. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. <i>Ann Rheum Dis</i>. 2004;63(12):1594-1600.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etanercept-including-biosimilars-of-etanercept-drug-information/abstract-text/15345498/pubmed\" target=\"_blank\" id=\"15345498\">15345498</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2014;109(7):950-966.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etanercept-including-biosimilars-of-etanercept-drug-information/abstract-text/24935270/pubmed\" target=\"_blank\" id=\"24935270\">24935270</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Data on file, Immunex Corporation.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol&mdash;United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etanercept-including-biosimilars-of-etanercept-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"14613288\"></a>Davis JC Jr, Van Der Heijde D, Braun J, et al; Enbrel Ankylosing Spondylitis Study Group. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. <i>Arthritis Rheum</i>. 2003;48(11):3230-3236.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etanercept-including-biosimilars-of-etanercept-drug-information/abstract-text/14613288/pubmed\" target=\"_blank\" id=\"14613288\">14613288</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Enbrel (etanercept) [prescribing information]. Thousand Oaks, CA: Immunex Corp; October 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Enbrel (etanercept) [product monograph]. Mississauga, Canada: Amgen Canada Inc; September 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Erelzi (etanercept) [prescribing information]. Princeton, NJ: Sandoz Inc; August 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Feldmann M, Brennan FM, and Maini RN, &ldquo;Role of Cytokines in Rheumatoid Arthritis,&rdquo; <i>Annu Rev Immunol</i>, 1996, 14:397-440.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etanercept-including-biosimilars-of-etanercept-drug-information/abstract-text/8717520/pubmed\" target=\"_blank\" id=\"8717520\">8717520</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Felson DT, Anderson JJ, Boers M, et al, &ldquo;American College of Rheumatology. Preliminary Definition of Improvement in Rheumatoid Arthritis,&rdquo; <i>Arthritis Rheum</i>, 1995, 38(6):727-35.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etanercept-including-biosimilars-of-etanercept-drug-information/abstract-text/7779114/pubmed\" target=\"_blank\" id=\"7779114\">7779114</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fisher CJ Jr, Agosti JM, Opal SM, et al, &ldquo;Treatment of Septic Shock With the Tumor Necrosis Factor Receptor:Fc Fusion Protein. The Soluble TNF Receptor Sepsis Study Group,&rdquo; <i>N Engl J Med</i>, 1996, 334(26):1697-702.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etanercept-including-biosimilars-of-etanercept-drug-information/abstract-text/8637514/pubmed\" target=\"_blank\" id=\"8637514\">8637514</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12115173\"></a>Genovese MC, Bathon JM, Martin RW, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. <i>Arthritis Rheum</i>. 2002;46(6):1443-1450.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etanercept-including-biosimilars-of-etanercept-drug-information/abstract-text/12115173/pubmed\" target=\"_blank\" id=\"12115173\">12115173</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Giannini EH, Ruperto N, Ravelli A, et al, &ldquo;Preliminary Definition of Improvement in Juvenile Arthritis,&rdquo; <i>Arthritis Rheum</i>, 1997, 40(7):1202-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etanercept-including-biosimilars-of-etanercept-drug-information/abstract-text/9214419/pubmed\" target=\"_blank\" id=\"9214419\">9214419</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etanercept-including-biosimilars-of-etanercept-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levine JE, Paczesny S, Mineishi S, et al, &ldquo;Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease,&rdquo; <i>Blood</i>, 2008, 111(4):2470-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etanercept-including-biosimilars-of-etanercept-drug-information/abstract-text/18042798/pubmed\" target=\"_blank\" id=\"18042798\">18042798</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lopez-Oilvo MA, Tayar JH, Martinez-Lopez JA, et al, &ldquo;Risk of Malignancies in Patients With Rheumatoid Arthritis Treated With Biologic Therapy: A Meta-Analysis,&rdquo; <i>JAMA</i>, 2012, 308(9): 898-908.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etanercept-including-biosimilars-of-etanercept-drug-information/abstract-text/22948700/pubmed\" target=\"_blank\" id=\"22948700\">22948700</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lovell DJ, Reiff A, Jones OY, et al. Long-Term Safety and Efficacy of Etanercept in Children With Polyarticular-Course Juvenile Rheumatoid Arthritis. <i>Arthritis Rheum</i>. 2006;54(6):1987-1994.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etanercept-including-biosimilars-of-etanercept-drug-information/abstract-text/16732547/pubmed\" target=\"_blank\" id=\"16732547\">16732547</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. <i>Lancet.</i> 2000;356(9227):385-390.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etanercept-including-biosimilars-of-etanercept-drug-information/abstract-text/10972371/pubmed\" target=\"_blank\" id=\"10972371\">10972371</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15248226\"></a>Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. <i>Arthritis Rheum</i>. 2004;50(7):2264-2272.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etanercept-including-biosimilars-of-etanercept-drug-information/abstract-text/15248226/pubmed\" target=\"_blank\" id=\"15248226\">15248226</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Moreland LW, Baumgartner SW, Schiff MH, et al, &ldquo;Treatment of Rheumatoid Arthritis With a Recombinant Human Tumor Necrosis Factor Receptor (p75)-Fc Fusion Protein,&rdquo; <i>N Engl J Med</i>, 1997, 337(3):141-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etanercept-including-biosimilars-of-etanercept-drug-information/abstract-text/9219699/pubmed\" target=\"_blank\" id=\"9219699\">9219699</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;New Drugs for Rheumatoid Arthritis,&rdquo; <i>Med Lett Drugs Ther</i>, 1998, 40(1040):110-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etanercept-including-biosimilars-of-etanercept-drug-information/abstract-text/9844625/pubmed\" target=\"_blank\" id=\"9844625\">9844625</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in <i>Circulation</i>. 2016;134(12):e261]. <i>Circulation</i>. 2016;134(6):e32-e69.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etanercept-including-biosimilars-of-etanercept-drug-information/abstract-text/27400984/pubmed\" target=\"_blank\" id=\"27400984\">27400984</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26775775\"></a>Paller AS, Siegfried EC, Pariser DM, et al. Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis. <i>J Am Acad Dermatol</i>. 2016;74(2):280-287.e1-e3. doi: 10.1016/j.jaad.2015.09.056.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etanercept-including-biosimilars-of-etanercept-drug-information/abstract-text/26775775/pubmed\" target=\"_blank\" id=\"26775775\">26775775</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Parakkal D, Sifuentes H, Semer R, et al, &ldquo;Hepatosplenic T-Cell Lymphoma in Patients Receiving TNF-&alpha; Inhibitor Therapy: Expanding the Groups at Risk,&rdquo; <i>Eur J Gastroenterol Hepatol</i>, 2011, 23(12):1150-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etanercept-including-biosimilars-of-etanercept-drug-information/abstract-text/21941193/pubmed\" target=\"_blank\" id=\"21941193\">21941193</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ramey DR, Fries JF, and Singh G, &ldquo;The Health Assessment Questionnaire 1995 - Status and Review,&rdquo; Spilker B, ed, <i>Quality of Life and Pharmacoeconomics in Clinical Trials</i>, 2nd ed, Philadelphia, PA: Lippincott-Raven, 1996.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Saxne T, Palladino MA Jr, Heinegard D, et al, &ldquo;Detection of Tumor Necrosis Factor Alpha but Not Tumor Necrosis Factor Beta in Rheumatoid Arthritis Synovial Fluid and Serum,&rdquo; <i>Arthritis Rheum</i>, 1988, 31(8):1041-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etanercept-including-biosimilars-of-etanercept-drug-information/abstract-text/3136775/pubmed\" target=\"_blank\" id=\"3136775\">3136775</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Singh JA, Furst DE, Bharat A, et al, &ldquo;2012 Update of the 2008 American College of Rheumatology Recommendations for the Use of Disease-Modifying Antirheumatic Drugs and Biologic Agents in the Treatment of Rheumatoid Arthritis,&rdquo; <i>Arthritis Care Res (Hoboken)</i>, 2012, 64(5):625-39.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etanercept-including-biosimilars-of-etanercept-drug-information/abstract-text/22473917/pubmed\" target=\"_blank\" id=\"22473917\">22473917</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smith CA, Farrah T, and Goodwin RG, &ldquo;The TNF Receptor Superfamily of Cellular and Viral Proteins: Activation, Costimulation, and Death,&rdquo; <i>Cell</i>, 1994, 76(6):959-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etanercept-including-biosimilars-of-etanercept-drug-information/abstract-text/8137429/pubmed\" target=\"_blank\" id=\"8137429\">8137429</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    van Oosten BW, Barkhof F, Truyen L, et al, &ldquo;Increased MRI Activity and Immune Activation in Two Multiple Sclerosis Patients Treated With the Monoclonal Anti-tumor Necrosis Factor Antibody cA2,&rdquo; <i>Neurology</i>, 1996, 47(6):1531-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etanercept-including-biosimilars-of-etanercept-drug-information/abstract-text/8960740/pubmed\" target=\"_blank\" id=\"8960740\">8960740</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. <i>N Engl J Me</i><i>d</i>. 2005;352(4):351-361.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etanercept-including-biosimilars-of-etanercept-drug-information/abstract-text/15673801/pubmed\" target=\"_blank\" id=\"15673801\">15673801</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weinblatt ME, Kremer JM, Bankhurst AD, et al, &ldquo;A Trial of Etanercept, A Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, in Patients With Rheumatoid Arthritis Receiving Methotrexate,&rdquo; <i>N Engl J Med</i>, 1999, 340(4):253-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etanercept-including-biosimilars-of-etanercept-drug-information/abstract-text/9920948/pubmed\" target=\"_blank\" id=\"9920948\">9920948</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wooley PH, Dutcher J, Widmer MB, et al, &ldquo;Influence of a Recombinant Human Soluble Tumor Necrosis Factor Receptor FC Fusion Protein on Type II Collagen-Induced Arthritis in Mice,&rdquo; <i>J Immunol</i>, 1993, 151(11):6602-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etanercept-including-biosimilars-of-etanercept-drug-information/abstract-text/8245488/pubmed\" target=\"_blank\" id=\"8245488\">8245488</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15703360\"></a>Yim DS, Zhou H, Buckwalter M, Nestorov I, Peck CC, Lee H. Population pharmacokinetic analysis and simulation of the time-concentration profile of etanercept in pediatric patients with juvenile rheumatoid arthritis. <i>J Clin Pharmacol</i>. 2005;45(3):246-256.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etanercept-including-biosimilars-of-etanercept-drug-information/abstract-text/15703360/pubmed\" target=\"_blank\" id=\"15703360\">15703360</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8925 Version 171.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F6655343\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F167887\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F167888\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F167912\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F167891\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F167901\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F167892\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F14471443\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F14471444\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F167868\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F167854\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F51112571\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F48847984\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7874648\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F167870\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F167869\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25473874\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F7914269\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F167861\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F167873\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F167858\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299288\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F167863\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F167876\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F167877\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F6045563\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F167857\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F167872\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F167875\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F167878\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8925|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=etanercept-including-biosimilars-of-etanercept-patient-drug-information\" class=\"drug drug_patient\">Etanercept (including biosimilars of etanercept): Patient drug information</a></li><li><a href=\"topic.htm?path=etanercept-including-biosimilars-of-etanercept-pediatric-drug-information\" class=\"drug drug_pediatric\">Etanercept (including biosimilars of etanercept): Pediatric drug information</a></li></ul></div></div>","javascript":null}